BUSINESS
Sawai Chief Wants Expert Panel to Discuss Delisting of Generics Deemed No Longer Necessary
Sawai Pharmaceutical President Kenzo Sawai on August 23 called on a soon-to-be-launched expert panel on drug distribution and pricing to discuss the possibility of allowing the delisting of listed medicines, particularly generics, when they are deemed no longer necessary. “There…
To read the full story
Related Article
BUSINESS
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
- Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
- Create BioVentures Sets Sail as Drug Discovery Bridge Builder
June 19, 2026
- Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
June 19, 2026
- Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





